A 101 - Aclaris Therapeutics

Drug Profile

A 101 - Aclaris Therapeutics

Alternative Names: A 101 40%; A 101 45%; A-101 - Aclaris; V-101 - Aclaris

Latest Information Update: 01 Mar 2017

Price : $50

At a glance

  • Originator Aclaris Therapeutics
  • Class Skin disorder therapies
  • Mechanism of Action Oxidoreductase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Seborrhoeic keratosis

Highest Development Phases

  • Preregistration Seborrhoeic keratosis
  • Phase II Warts

Most Recent Events

  • 15 Mar 2017 Aclaris Therapeutics plans two phase II trials for Warts in USA
  • 27 Feb 2017 Preregistration for Seborrhoeic keratosis in USA (Topical)
  • 01 Dec 2016 Aclaris Therapeutics completes a phase II trial in Warts in USA (NCT02669862)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top